201 related articles for article (PubMed ID: 10870845)
1. Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-L-iduronidase in immunized rats.
Turner CT; Hopwood JJ; Brooks DA
Mol Genet Metab; 2000 Apr; 69(4):277-85. PubMed ID: 10870845
[TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy in feline mucopolysaccharidosis I.
Kakkis ED; Schuchman E; He X; Wan Q; Kania S; Wiemelt S; Hasson CW; O'Malley T; Weil MA; Aguirre GA; Brown DE; Haskins ME
Mol Genet Metab; 2001 Mar; 72(3):199-208. PubMed ID: 11243725
[TBL] [Abstract][Full Text] [Related]
3. Common antigenicity for two glycosidases.
Kakavanos R; Lehn P; Callebaut I; Meikle PJ; Parkinson-Lawrence EJ; Hopwood JJ; Brooks DA
FEBS Lett; 2006 Jan; 580(1):87-92. PubMed ID: 16359666
[TBL] [Abstract][Full Text] [Related]
4. Immune response to enzyme replacement therapy: single epitope control of antigen distribution from circulation.
Glaros EN; Turner CT; Parkinson EJ; Hopwood JJ; Brooks DA
Mol Genet Metab; 2002; 77(1-2):127-35. PubMed ID: 12359140
[TBL] [Abstract][Full Text] [Related]
5. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M
Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431
[TBL] [Abstract][Full Text] [Related]
6. Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats.
Turner CT; Hopwood JJ; Bond CS; Brooks DA
Mol Genet Metab; 1999 Jul; 67(3):194-205. PubMed ID: 10381327
[TBL] [Abstract][Full Text] [Related]
7. Enzyme-replacement therapy in mucopolysaccharidosis I.
Kakkis ED; Muenzer J; Tiller GE; Waber L; Belmont J; Passage M; Izykowski B; Phillips J; Doroshow R; Walot I; Hoft R; Neufeld EF
N Engl J Med; 2001 Jan; 344(3):182-8. PubMed ID: 11172140
[TBL] [Abstract][Full Text] [Related]
8. Pre-stem cell transplantation enzyme replacement therapy in Hurler syndrome does not lead to significant antibody formation or delayed recovery of the endogenous enzyme post-transplant: a case report.
Soni S; Hente M; Breslin N; Hersh J; Whitley C; Cheerva A; Bertolone S
Pediatr Transplant; 2007 Aug; 11(5):563-7. PubMed ID: 17631030
[TBL] [Abstract][Full Text] [Related]
9. Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I.
Kakavanos R; Turner CT; Hopwood JJ; Kakkis ED; Brooks DA
Lancet; 2003 May; 361(9369):1608-13. PubMed ID: 12747881
[TBL] [Abstract][Full Text] [Related]
10. Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy.
Langereis EJ; van Vlies N; Church HJ; Geskus RB; Hollak CE; Jones SA; Kulik W; van Lenthe H; Mercer J; Schreider L; Tylee KL; Wagemans T; Wijburg FA; Bigger BW
Mol Genet Metab; 2015 Feb; 114(2):129-37. PubMed ID: 25467058
[TBL] [Abstract][Full Text] [Related]
11. Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I.
Kakkis E; Lester T; Yang R; Tanaka C; Anand V; Lemontt J; Peinovich M; Passage M
Proc Natl Acad Sci U S A; 2004 Jan; 101(3):829-34. PubMed ID: 14715900
[TBL] [Abstract][Full Text] [Related]
12. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.
Yogalingam G; Guo XH; Muller VJ; Brooks DA; Clements PR; Kakkis ED; Hopwood JJ
Hum Mutat; 2004 Sep; 24(3):199-207. PubMed ID: 15300847
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase).
Wraith JE; Beck M; Lane R; van der Ploeg A; Shapiro E; Xue Y; Kakkis ED; Guffon N
Pediatrics; 2007 Jul; 120(1):e37-46. PubMed ID: 17606547
[TBL] [Abstract][Full Text] [Related]
14. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.
Kakkis ED; McEntee MF; Schmidtchen A; Neufeld EF; Ward DA; Gompf RE; Kania S; Bedolla C; Chien SL; Shull RM
Biochem Mol Med; 1996 Aug; 58(2):156-67. PubMed ID: 8812735
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the human lysosomal enzyme alpha-L-iduronidase in Chinese hamster ovary cells.
Kakkis ED; Matynia A; Jonas AJ; Neufeld EF
Protein Expr Purif; 1994 Jun; 5(3):225-32. PubMed ID: 7950365
[TBL] [Abstract][Full Text] [Related]
16. [Hurler syndrome. Early diagnosis and successful enzyme replacement therapy: a new therapeutic approach. Case report].
Dupont C; El Hachem C; Harchaoui S; Ribault V; Amiour M; Guillot M; Maire I; Froissart R; Guffon-Fouilhoux N
Arch Pediatr; 2008 Jan; 15(1):45-9. PubMed ID: 18162380
[TBL] [Abstract][Full Text] [Related]
17. Prediction of neuropathology in mucopolysaccharidosis I patients.
Fuller M; Brooks DA; Evangelista M; Hein LK; Hopwood JJ; Meikle PJ
Mol Genet Metab; 2005 Jan; 84(1):18-24. PubMed ID: 15639191
[TBL] [Abstract][Full Text] [Related]
18. Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies.
Xue Y; Richards SM; Mahmood A; Cox GF
Mol Genet Metab; 2016 Apr; 117(4):419-26. PubMed ID: 26920513
[TBL] [Abstract][Full Text] [Related]
19. Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice.
Chung S; Ma X; Liu Y; Lee D; Tittiger M; Ponder KP
Mol Genet Metab; 2007 Feb; 90(2):181-92. PubMed ID: 16979922
[TBL] [Abstract][Full Text] [Related]
20. Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models.
Brooks DA
Mol Genet Metab; 1999 Oct; 68(2):268-75. PubMed ID: 10527678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
